Edgewise Therapeutics
Edgewise Therapeutics Inc is an American clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative oral therapies for the treatment of severe rare muscle disorders, prominently featuring treatments for Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy. The company utilizes its proprietary muscle-targeted drug discovery platform to develop small-molecule therapies designed to protect muscle tissue from contraction-induced injury and degeneration. Its core business activities encompass preclinical and clinical biopharmaceutical research, drug discovery, clinical trial execution, and regulatory compliance. As a clinical-stage biotechnology enterprise, the company generates minimal commercial revenue and finances its drug research pipeline through public equity offerings and pharmaceutical collaborations. Edgewise Therapeutics holds a pioneering market position in targeted muscle disease therapeutics. The company is headquartered in Boulder, Colorado, United States, and its common stock trades on the Nasdaq Global Select Market.
4 of the funds FundTelligence covers report a position in Edgewise Therapeutics.
- Legal name
- Edgewise Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
Funds holding Edgewise Therapeutics
- SEB Läkemedelsfond — SEB · 0.44 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.32 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.04 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)